Get started
Author

Rao Mulpuri

The Oxylipin Pathway in Arabidopsis
2002 · Robert A. Creelman, Rao Mulpuri · The Arabidopsis Book · 111
PDF
Collaborating to Compete: Blood Profiling Atlas in Cancer (BloodPAC) Consortium
2017 · RL Grossman, B Abel, et al. · Clinical Pharmacology & Therapeutics · 47
PDF
A Noninvasive Blood-based Combinatorial Proteomic Biomarker Assay to Detect Breast Cancer in Women Under the Age of 50 Years
2017 · Ana P. Lourenco, Kasey L. Benson, et al. · Clinical Breast Cancer · 31
Integration of Serum Protein Biomarker and Tumor Associated Autoantibody Expression Data Increases the Ability of a Blood-Based Proteomic Assay to Identify Breast Cancer
2016 · Meredith C. Henderson, Alan B. Hollingsworth, et al. · PLoS ONE · 31
PDF
A Noninvasive Blood-based Combinatorial Proteomic Biomarker Assay to Detect Breast Cancer in Women over age 50 with BI-RADS 3, 4, or 5 Assessment
2018 · Meredith C. Henderson, Michael Silver, et al. · Clinical Cancer Research · 29
Breast density does not impact the ability of Videssa® Breast to detect breast cancer in women under age 50
2017 · David E. Reese, Meredith C. Henderson, et al. · PLoS ONE · 7
PDF
Abstract P6-03-03: Not presented
2018 · MC Henderson, M Silver, et al. · Cancer Research · 2
A Combinatorial Proteomic Biomarker Assay to Detect Ovarian Cancer in Women
2018 · Meredith C Henderson, Michael Silver, et al. · Biomarkers in Cancer · 2
Supplementary Tables from A Noninvasive Blood-based Combinatorial Proteomic Biomarker Assay to Detect Breast Cancer in Women over age 50 with BI-RADS 3, 4, or 5 Assessment
2023 · Meredith C. Henderson, Michael Silver, et al.
Figure S4 from A Noninvasive Blood-based Combinatorial Proteomic Biomarker Assay to Detect Breast Cancer in Women over age 50 with BI-RADS 3, 4, or 5 Assessment
2023 · Meredith C. Henderson, Michael Silver, et al.
Figure S2 from A Noninvasive Blood-based Combinatorial Proteomic Biomarker Assay to Detect Breast Cancer in Women over age 50 with BI-RADS 3, 4, or 5 Assessment
2023 · Meredith C. Henderson, Michael Silver, et al.
Figure S1 from A Noninvasive Blood-based Combinatorial Proteomic Biomarker Assay to Detect Breast Cancer in Women over age 50 with BI-RADS 3, 4, or 5 Assessment
2023 · Meredith C. Henderson, Michael Silver, et al.
Figure S5 from A Noninvasive Blood-based Combinatorial Proteomic Biomarker Assay to Detect Breast Cancer in Women over age 50 with BI-RADS 3, 4, or 5 Assessment
2023 · Meredith C. Henderson, Michael Silver, et al.
Figure S3 from A Noninvasive Blood-based Combinatorial Proteomic Biomarker Assay to Detect Breast Cancer in Women over age 50 with BI-RADS 3, 4, or 5 Assessment
2023 · Meredith C. Henderson, Michael Silver, et al.
Supplementary Tables from A Noninvasive Blood-based Combinatorial Proteomic Biomarker Assay to Detect Breast Cancer in Women over age 50 with BI-RADS 3, 4, or 5 Assessment
2023 · Meredith C. Henderson, Michael Silver, et al.
PDF
Figure S4 from A Noninvasive Blood-based Combinatorial Proteomic Biomarker Assay to Detect Breast Cancer in Women over age 50 with BI-RADS 3, 4, or 5 Assessment
2023 · Meredith C. Henderson, Michael Silver, et al.
Figure S3 from A Noninvasive Blood-based Combinatorial Proteomic Biomarker Assay to Detect Breast Cancer in Women over age 50 with BI-RADS 3, 4, or 5 Assessment
2023 · Meredith C. Henderson, Michael Silver, et al.
Figure S1 from A Noninvasive Blood-based Combinatorial Proteomic Biomarker Assay to Detect Breast Cancer in Women over age 50 with BI-RADS 3, 4, or 5 Assessment
2023 · Meredith C. Henderson, Michael Silver, et al.
Figure S5 from A Noninvasive Blood-based Combinatorial Proteomic Biomarker Assay to Detect Breast Cancer in Women over age 50 with BI-RADS 3, 4, or 5 Assessment
2023 · Meredith C. Henderson, Michael Silver, et al.
Data from A Noninvasive Blood-based Combinatorial Proteomic Biomarker Assay to Detect Breast Cancer in Women over age 50 with BI-RADS 3, 4, or 5 Assessment
2023 · Meredith C. Henderson, Michael Silver, et al.
Data from A Noninvasive Blood-based Combinatorial Proteomic Biomarker Assay to Detect Breast Cancer in Women over age 50 with BI-RADS 3, 4, or 5 Assessment
2023 · Meredith C. Henderson, Michael Silver, et al.
Figure S2 from A Noninvasive Blood-based Combinatorial Proteomic Biomarker Assay to Detect Breast Cancer in Women over age 50 with BI-RADS 3, 4, or 5 Assessment
2023 · Meredith C. Henderson, Michael Silver, et al.
Abstract P4-01-07: A liquid biopsy test for breast cancer detection provides consistent diagnostic results in patients over six months
2017 · KL Benson, MC Henderson, et al. · Cancer Research
Abstract P1-02-08: Provista-002: A prospective, multi-center study to determine the effectiveness of a biomarker assay to distinguish benign from invasive breast cancer in women with BI-RADS 3, 4 and 5 imaging reports
2017 · J Wolf, A Lourenco, et al. · Cancer Research
Abstract P5-03-03: A blood-based proteomic Videssa® breast assay performs comparably in women with dense and non-dense breasts
2017 · M Silver, Q Tran, et al. · Cancer Research
Works count: 30
Citation count: 260
H-index: 6
I10-index: 5
Year
Topic
Type